[go: up one dir, main page]

AR076588A1 - VAGINAL RELEASE SYSTEM - Google Patents

VAGINAL RELEASE SYSTEM

Info

Publication number
AR076588A1
AR076588A1 ARP100101718A ARP100101718A AR076588A1 AR 076588 A1 AR076588 A1 AR 076588A1 AR P100101718 A ARP100101718 A AR P100101718A AR P100101718 A ARP100101718 A AR P100101718A AR 076588 A1 AR076588 A1 AR 076588A1
Authority
AR
Argentina
Prior art keywords
drospirenone
membrane
compartment
release system
estrogen
Prior art date
Application number
ARP100101718A
Other languages
Spanish (es)
Inventor
Christine Talling
Svante Holmberg
Antti Keinanen
Original Assignee
Bayer Schering Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Oy filed Critical Bayer Schering Pharma Oy
Publication of AR076588A1 publication Critical patent/AR076588A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un sistema de liberacion intravaginal para la liberacion controlada de drospirenona o drospirenona y un estrogeno durante un período de tiempo prolongado, el sistema está caracterizado porque comprende por lo menos un compartimiento, dicho uno o cada compartimiento comprende un nucleo y una membrana que envuelve al nucleo, dicho nucleo y dicha membrana están constituidos esencialmente por una composicion de polímeros igual o diferente, en donde por lo menos un compartimiento comprende: a) drospirenona o un profármaco de la misma; o b) una mezcla de drospirenona o su profármaco y un estrogeno. Reivindicacion 7: Un sistema de liberacion intravaginal de acuerdo con cualquiera de las reivindicaciones 1 a 6, caracterizado porque el nucleo y la membrana están hechos de una composicion de elastomero basada en siloxano que comprende por lo menos un elastomero y posiblemente un polímero no reticulado.Claim 1: An intravaginal release system for the controlled release of drospirenone or drospirenone and an estrogen for a prolonged period of time, the system is characterized in that it comprises at least one compartment, said one or each compartment comprising a core and a membrane that It envelops the nucleus, said nucleus and said membrane are essentially constituted by a composition of the same or different polymers, wherein at least one compartment comprises: a) drospirenone or a prodrug thereof; or b) a mixture of drospirenone or its prodrug and an estrogen. Claim 7: An intravaginal delivery system according to any one of claims 1 to 6, characterized in that the core and membrane are made of a siloxane-based elastomer composition comprising at least one elastomer and possibly a non-crosslinked polymer.

ARP100101718A 2009-05-20 2010-05-18 VAGINAL RELEASE SYSTEM AR076588A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20095563A FI20095563L (en) 2009-05-20 2009-05-20 Vaginal delivery system

Publications (1)

Publication Number Publication Date
AR076588A1 true AR076588A1 (en) 2011-06-22

Family

ID=40680743

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101718A AR076588A1 (en) 2009-05-20 2010-05-18 VAGINAL RELEASE SYSTEM

Country Status (4)

Country Link
AR (1) AR076588A1 (en)
FI (1) FI20095563L (en)
TW (1) TW201043208A (en)
WO (1) WO2010133757A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937335B2 (en) * 2011-06-06 2018-04-10 Oak Crest Institute Of Science Drug delivery device employing wicking release window
PE20181214A1 (en) * 2015-12-21 2018-07-24 Bayer Oy METHOD FOR MANUFACTURING A DEVICE FOR THE ADMINISTRATION OF DRUGS AND A DEVICE FOR THE ADMINISTRATION OF DRUGS MADE ACCORDING TO THE METHOD
AU2019275409B2 (en) 2018-05-24 2024-08-15 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
JP2021524841A (en) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー Implantable device for sustained release of macromolecular drug compounds
CA3122847A1 (en) * 2018-12-11 2020-06-18 Lupin Inc. Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE SUSTAINED RELEASE OF A MACROMOLECULAR DRUG COMPOUND

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
FI95768C (en) * 1993-06-17 1996-03-25 Leiras Oy Intravaginal dosing system
DE19606355A1 (en) * 1996-02-12 1997-08-14 Schering Ag Contraceptive release systems with antiviral and / or antibacterial effects
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070004693A1 (en) * 2005-06-16 2007-01-04 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
CN101237851B (en) * 2005-06-16 2013-09-18 沃纳奇尔科特有限责任公司 Estrogenic compositions for vaginal administration
IE20050723A1 (en) * 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
AR066166A1 (en) * 2007-09-21 2009-07-29 Organon Nv DRUG SUPPLY SYSTEM
US20090099149A1 (en) * 2007-10-11 2009-04-16 Wyeth Bioadhesive film
EP2062568A1 (en) * 2007-11-22 2009-05-27 Bayer Schering Pharma Oy Vaginal delivery system
PL2062569T3 (en) * 2007-11-22 2011-10-31 Bayer Oy Vaginal delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
GB2475013A (en) * 2008-09-16 2011-05-04 Playtex Products Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
FI121000B (en) * 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginal delivery system and method for its preparation

Also Published As

Publication number Publication date
FI20095563A7 (en) 2010-11-21
WO2010133757A1 (en) 2010-11-25
FI20095563L (en) 2010-11-21
TW201043208A (en) 2010-12-16
FI20095563A0 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
AR076588A1 (en) VAGINAL RELEASE SYSTEM
PA8805001A1 (en) VAGINAL ADMINISTRATION SYSTEM
UY32327A (en) LISOPHOSPHATIDIC ACID RECEIVERS ANTAGONISTS
ECSP11011546A (en) PHARMACEUTICAL COMPOSITION FOR EMERGENCY ANTI-CONCEPT
BR112012013926A2 (en) selective cell lysis
PE20100057A1 (en) INTRAUTERINE DELIVERY SYSTEM FOR THE CONTROLLED RELEASE OF PROGESTAGEN
MX2020002727A (en) NEW USE FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS.
BR112012010136A2 (en) pluripotent stem cells
UY32659A (en) PIRAZINILPIRAZOLES
CL2011002017A1 (en) Modular block for civil works, it comprises a base body, a structural projection and interconnection means to blocks belonging to the same modular system, having around said structural projection a certain space designed to define a part of a channel; modular system; use of a modular block.
BR112015017174A2 (en) preparation of modified extracellular matrix manipulated tissue nerve grafts for repair of peripheral nerve injury
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
ES2479542T1 (en) Methods and compositions for use in cell therapies
BRPI0819936A2 (en) Pharmaceutical preparation, method for producing dendritic cells, dendritic cells, pharmaceutical composition, and use of a dendritic cell or preparation.
WO2011008495A3 (en) Arginase formulations and methods
CL2008003549A1 (en) Glucocorticoid derived compounds; preparation procedures; pharmaceutical composition; pharmaceutical combination; and use for the treatment of skin diseases such as eczema, nose, throat and lung conditions such as rhinitis or asthma, inflammatory bowel, eye and autoimmune diseases.
BRPI0818420A2 (en) MIXED MOTHER MEMBRANE.
GB201700621D0 (en) Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CL2011000570A1 (en) Compounds derived from 3- (4-cyano-phenyl) -pyrazol-5-carboxamide, progesterone receptor modulators; pharmaceutical composition; and its use for the treatment of endometriosis, uterine fibromiomas, primary or secondary dysmenorrhea, among others.
CU20100056A7 (en) METHOD FOR INHIBITING THE REPLICATION OF HIV IN CELLS OF MAMMALS
UY32005A (en) STRATRIENE DERIVATIVES THAT INCLUDE HETEROCYCLIC BIOISOSTERS FOR PHENOLIC RING A
ATE508734T1 (en) VAGINAL RELEASE SYSTEM
GT201300022A (en) USE OF CELLULAR CONCRETE AGENTS AND MANUFACTURING PROCEDURE
CU20100102A7 (en) VAGINAL ADMINISTRATION SYSTEM
GB2511658A (en) Defoaming compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure